Patents by Inventor Christopher G. Nasveschuk

Christopher G. Nasveschuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Degraders and Degrons for targeted protein degradation
    Patent number: 11524949
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: December 13, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • TARGETED PROTEIN DEGRADATION
    Publication number: 20220372016
    Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.
    Type: Application
    Filed: June 18, 2021
    Publication date: November 24, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Katrina L. Jackson, Minsheng He, Yanke Liang, Mark E. Fitzgerald, Victoria Garza
  • C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20220313826
    Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: November 30, 2020
    Publication date: October 6, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
  • N/O-linked Degrons and Degronimers for protein degradation
    Patent number: 11459335
    Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: October 4, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
  • DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
    Publication number: 20220251061
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 11, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • COMPOUNDS FOR TARGETED DEGRADATION OF BRD9
    Publication number: 20220098194
    Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 31, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakin, Jeremy L. Yap
  • Spirocyclic degronimers for target protein degradation
    Patent number: 11185592
    Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 30, 2021
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
  • COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
    Publication number: 20210198256
    Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.
    Type: Application
    Filed: March 4, 2021
    Publication date: July 1, 2021
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Rhamy Zeid
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20210070763
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 11, 2021
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20210032245
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 4, 2021
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS
    Publication number: 20210009559
    Abstract: The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
  • N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
    Publication number: 20200140456
    Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
  • Therapeutic compounds and uses thereof
    Patent number: 10358437
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 23, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor
  • Therapeutic compounds and uses thereof
    Patent number: 10316023
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 11, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor
  • Therapeutic compounds and uses thereof
    Patent number: 10308614
    Abstract: The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: June 4, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor
  • Therapeutic compounds and uses thereof
    Patent number: 10301253
    Abstract: Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 28, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Martin Duplessis, Victor S. Gehling, Andrew Charles Good, Jean-Christophe Harmange, Yves LeBlanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Therapeutic compounds and uses thereof
    Patent number: 10280149
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: May 7, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Birong Zhang
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190125737
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 2, 2019
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Therapeutic compounds and uses thereof
    Patent number: 10258603
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 16, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: RE47428
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 11, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani